Title: Terminal tracheal cells of *Drosophila* are immune privileged to maintain their Foxo-dependent structural plasticity

Authors: Judith Bossen [1,2*], Reshmi Raveendran[1], Jingjing He[1] & Thomas Roeder[1,2*]

Affiliations:

[1] Kiel University, Zoology, Dept. Molecular Physiology; Kiel, Germany.

[2] Airway Research Center North (ARCN), German Center for Lung Research (DZL).

*Corresponding authors. Judith Bossen, email: jbossen@zoologie.uni-kiel.de, Thomas Roeder, email: troeder@zoologie.uni-kiel.de.

Abstract: Respiratory organs fulfill several tasks, of which gas exchange is the most important. This function is also true for the *Drosophila* respiratory organ, the tracheal system, in which the tracheal terminal cells (TTCs), the functional equivalents of the mammalian lung's alveoli, are the structures where gas exchange occurs. To cope with the plethora of inhaled bacteria, fungi, and viruses, the trachea, like all airway organs, developed a sophisticated innate immune system to protect its large surface area. Bacterial infection of the Drosophila larval tracheal system induced a robust immune response throughout the entire airway epithelium, except for the TTCs that lacked this response. TTCs do not express the membrane-associated peptidoglycan recognition receptor PGRP-LC, which we assume protects these susceptible cells from Immune deficiency (Imd) pathway activation and JNK-mediated cell death. Thus, TTCs can be considered an immune-privileged cell type compared to the rest of the tracheal tissue. Targeted overexpression of PGRP-LCx in these cells led to a significant reduction in branching, cell damage, and ultimately cell death, which depletion of AP-1 or foxo could rescue. We hypothesize that the structural plasticity of TTCs in response to nutritional cues and hypoxia is incompatible with a potent immune function. Both reactions, the structural plasticity, and the immune response, require the transcription factor foxo, and we showed that it is essential for structural plasticity. Thus, the immune-privileged status of TTCs is (presumably) a mechanism that ensures normal TTC function.

Short title: Terminal tracheal cells of *Drosophila* are immune privileged to maintain their Foxo-dependent structural plasticity.

INTRODUCTION

The tracheal system of *Drosophila* comprises three different parts: the main dorsal trunks, the smaller tracheal branches, and the terminal cells (*1, 2*). The tracheal terminal cells (TTCs) form the most distal part of the respiratory system. They are the site at which gas exchange takes place. TTCs fulfill an essential role by supplying all body organs with oxygen. To fulfill their task, even under ever-changing conditions, these cells possess a high degree of structural plasticity. For example, TTCs can sprout in response to local hypoxia (*3*), or in response to differences in nutrient availability (*4*); this process is analogous to angiogenesis in mammals. Sprouting is dependent on growth factors, as well as the hypoxia-inducible factor (HIF)-α homolog sima, again analogous to endothelial cells during angiogenesis in the mammalian vascular system (*3, 5, 6*).

The primary role of the proximal tracheal tubes is to conduct air to more distal parts. The epithelial cells lining these tubes can mount an effective immune response to infections (*7, 8*). This immune response is driven mainly by expression of several antimicrobial peptides (AMP) (*9, 10*). One out of the two major immune pathways operative in *Drosophila*, the immune deficiency (Imd) pathway, is solely responsible for responses in the larval airway epithelium; this is because the Toll pathway is not functional in these cells (*8*). The Imd signaling pathway is homologous to the human tumor necrosis factor-α (TNF-α) pathway, and converges on activation of NF-κB factors. Moreover, it is connected to c-Jun N-terminal kinase (JNK) signaling via transforming growth factor-β (TGF-β) activated kinase 1 (dTak1) (*11*). Infection of the airway system induces an immune response by the tracheal epithelium, which includes expression of canonical Imd and JNK target genes (*9, 12*). Chronic activation of tracheal immune signaling leads to marked structural changes in the epithelium (*13*). This tissue remodeling is mediated by JNK and its downstream transcription factor, forkhead box sub-group O (foxo), which is a as a terminal target of the epithelial immune system. FoxOs

are also central proteins of the insulin signaling pathway, which also plays an important role

in the structural plasticity of TTCs (*14–16*).

The present study shows that TTCs differ fundamentally from the rest of the tracheal

epithelium. In the case of a natural infection of the tracheal system, these cells show only a

negligible immune response. The very few TTCs that do show AMP expression are

structurally impaired. We found that TTCs are immune privileged. The Imd pathway in TTCs

is deactivated since the cells do not express the transmembrane peptidoglycan recognition

protein (PGRP)-LCx. Chronic activation of the Imd signaling pathway in TTCs leads to JNK-

dependent apoptosis. Therefore, we hypothesize that the immune privileged status of TTCs

maintains the normal function of foxo, which acts as a regulator of structural plasticity.

RESULTS

Tracheal infection revealed that AMP expression in terminal cells is rare

Drs-GFP larvae were infected with *Erwinia carotovora* for 24 h. These larvae express GFP

under the control of the *Drosomycin* (*Drs*) promoter, which is activated by a natural infection

of the trachea (*9*). GFP fluorescence was analyzed after 24 h, focusing on TTCs (Fig. 1).

Fluorescence was visible in all parts of the tracheal system except for TTCs (Fig. 1A, A', B,

B'; dashed lines). A total of 169 larvae were analyzed. All larvae with fluorescence detectable

in the dorsal branch (DB) were counted as GFP-positive (Fig. 1C). About 34% showed no

GFP signal, a finding consistent with previous observations (*10*). The remaining larvae

showed a GFP signal in the DB (65.7%); however, only 8.3% also showed fluorescence in

TTCs (Fig. 1D). Most of these few fluorescent TTCs showed clear structural differences from

TTCs without a GFP signal (Fig. 1E, E'). Although some cells had a normal structure (Fig.

1F, F'), most had shortened branches (Fig. 1E, E', G, G'), showed signs of melanization (Fig.

1H, arrow), or were no longer air-filled (Fig. 1H, arrowhead). These observations suggest that

an immune response in the TTC itself act on these cells.

Tracheal terminal cells do not express the Imd receptor PGRP-LCx

We wondered whether constitutive immune activation within the entire tracheal system would

exclude TTCs, as expected from the results of the infection experiments. To ensure that all

parts of the tracheal epithelium, including TTCs, were exposed to this activating stimulus, we

ectopically expressed the secreted (and intracellular) Imd pathway receptor PGRP-LE using

the *ppk4-Gal4* driver. AMP expression (a readout of the immune response) was visualized by

simultaneous expression of GFP-tagged *Drs* (Fig. 2). A strong immune response was

observed in the tracheal tissue, from the dorsal trunks down to the smaller branches (Fig. 2A–

C). While expression of *Drs* was consistent throughout most parts of the tracheal system, it

was completely absent from the most distal parts (Fig. 2B–E). Closer observation of the TTCs

revealed a distinct breakpoint in the GFP signal, which occurred at the proximal end of the

TTCs. This was true for TTCs attached to the outer cuticle (Fig. 2D) as well as for cells

attached to the intestine (Fig. 2E). Activation of the Imd pathway may not be fully functional

in these cells. To activate the Imd pathway successfully, secreted PGRP-LE has to bind to

transmembrane PGRP-LC, meaning that only cells expressing PGRP-LC can be activated (*17,*

18). Therefore, to investigate expression of PGRP-LC in the tracheal system, and specifically

in TTCs, we expressed *Gal4* under the control of the *PGRP-LC* promoter to drive concurrent

GFP expression (Fig. 2F, G). While GFP was visible throughout the entire tracheal system, it

was absent from all TTCs associated with the cuticle (Fig. 2F, F') and intestine (Fig. 2G, G').

To demonstrate that GFP expression can be visualized in TTCs, and that the lack of a signal

was not an artifact, expression of GFP in TTCs was driven by the tracheal driver *btl-Gal4*

(*btl-Gal4; UAS-GFP*) (Fig. 2H, I). TTCs on the dissected cuticle (Fig. 2H) and on the

intestine (Fig. 2I) expressed GFP. Thus, the data indicate that lack of expression of the Imd

pathway receptor PGRP-LC by TTCs is the reason for the difference between TTCs and cells

within the rest of the tracheal system.

Ectopic activation of PGRP-LCx in the tracheal system leads to death of TTCs

To further investigate the effects of immune responses on the tracheal system, we expressed

PGRP-LCx exclusively in TTCs (*PGRP-LCx*^{OE}; Fig. 3). We found that Imd-mediated immune

activation was restricted to these cells, as indicated by concurrent expression of GFP.

Compared with the widely branched and diversified TTCs in control samples (Fig. 3A),

PGRP-LCx-expressing TTCs showed a striking phenotype characterized by small and

shrunken cells (Fig. 3B). Measurement of TTC branches in *PGRP-LCx*-expressing larvae

revealed a significant reduction in the number and length of branches compared with the

controls (Fig. 3C, D). While cells in the control had about 14 branches, with a total length of

about 1550 µm, TTCs in PGRP-LCx[OE] insects had seven branches at the most, and the length

did not exceed 514 µm. This means that the branched surface of TTCs expressing *PGRP-LCx*

was reduced to less than one-third of that in controls. To investigate whether this cellular

phenotype has an impact on physiological oxygen supply, we exposed larvae to low oxygen

levels (2–3 %). Leaving the lawn under hypoxic conditions is the normal response of larvae,

and this response can be monitored over time. A significantly higher percentage of larvae with

TTCs overexpressing *PGRP-LCx* showed the escape phenotype after 15–25 minutes of

exposure (Fig. 3E). Activation of the Imd pathway by ectopic expression of *PGRP-LCx*

clearly impairs TTCs, not only with respect to induction of the shrunken phenotype, but also

to the functionality of these cells (i.e., the enhanced response to hypoxic conditions). To

elucidate whether this shrinking is part of an apoptotic cell program, we analyzed expression

of two apoptotic factors: head involution defective (hid) and reaper (rpr) (*19, 20*). We targeted

expression of these factors to TTCs using the *DSRF*-Gal4 driver line. Larvae expressing *hid;*

rpr showed a strong response to hypoxia by leaving the lawn at the very early larval stages;

these larvae did not survive (Fig. 3F). Since PGRP LCx-expressing larvae survived and did

not show this extreme phenotype, we examined Tak1 (a downstream component of the Imd

pathway). Expression of *Tak1* in TTCs also resulted in early larval death, similar to

expression of *hid; rpr* (Fig. 3F). Dissection of *hid; rpr*-expressing insects revealed a complete

absence of TTCs, with only rudimentary cell remnants connected to the intestine (Fig. 3G, H).

By contrast, overexpression of *PGRP-LCx* in TTCs resulted in similar cellular alterations,

although the cells remained alive. Nevertheless, the overall phenotype was strikingly similar

to that of apoptotic terminal cells (Fig. 3I).

Drosophila death caspase-1 (Dcp-1) is orthologous to mammalian Caspase-3, and is an

established marker of apoptosis (*21*). Immunohistochemical analysis using an anti-Dcp-1

antibody (Fig. 3J, K) revealed a lack of Dcp-1 in the control; however, strong GFP staining of

TTCs was visible (Fig. 3J-J"). TTCs expressing *PGRP-LCx* were positive for cleaved Dcp-1,

whereas counterstaining for GFP revealed reduced expression (Fig. 3K-K''). These data

clearly indicate that TTCs are undergoing apoptosis.

PGRP-LCx-induced terminal cell death is mediated by JNK signaling

The *Drosophila* Imd signaling pathway*,* which classically leads to activation of the Nf-κB

factor Relish, is homologous to the TNF-α signaling pathway in mammals. Similar to the

TNF-α pathway, the Imd pathway branches out to the JNK signaling pathway; the branch

point is Tak1 (Fig. 4A). To test whether the Nf-κB or the JNK branch is necessary to translate

PGRP-LCx activation in TTCs into triggering of apoptosis, we expressed these downstream

components in flies, which were then phenotyped. The number and length of the terminal

branches were measured and compared with those in control TTCs, and with the phenotype

produced by *PGRP-LCx* expression (Fig. 4B–F). Ectopic expression of an activated *Relish*

allele had no effect on the TTC branching phenotype (Fig. 4B, E, F). Expression of a

constitutively active form of dJNKK, *hemipterous* (hep^{CA}), resulted in a phenotype similar to

that caused by expression of the upstream receptor PGRP-LCx (Fig. 4C, E, F). Branching of

TTCs was reduced significantly, and did not differ significantly from that of TTCs with

PGRP-LCx expression. Overexpression of the wild-type JNK, *basket* (bsk^{OE}), also resulted in

reduced branching when compared with the control (Fig. 4D–F). These results suggest that

JNK activation is responsible for the TTC phenotype. To further support this hypothesis, the

cells were stained for the Nf-κB factor Relish (Rel) and for the phosphorylated JNK (pJNK)

basket (Fig. 4G, H).

Staining of the transcription factor Relish was observed throughout intestinal tissue, as well as

in TTCs, from controls, and in TTCs expressing *PGRP-LCx*; however, we observed no

translocation of Relish to the nucleus (Fig. 4G, arrow). In contrast to controls, *PGRP-LCx-*

expressing cells showed distinct nuclear staining by an anti-pJNK antibody (Fig. 4H, arrow).

Moreover, nuclear pJNK was also observed in the nuclei of surrounding intestinal cells. This

suggests that intestinal cells experience some additional JNK-mediated stress.

JNK-mediated TTC damage can be rescued by AP-1 and foxo depletion

The *Drosophila* JNK signaling pathway induces apoptosis (*22, 23*). The canonical

transcription factors (TFs) AP-1, foxo and Ets21C act downstream of Tak1 and JNK to

initiate transcription of target genes (Fig. 5A). Activation of each of these factors can lead to

expression of apoptotic genes (*24–27*). To evaluate whether one of these TFs is responsible

for the *PGRP-LCx^{OE}*-induced phenotype, we silenced each of them. This experimental

approach required the use of different controls with the *PGRP-LCx^{OE}* cassette located on

different chromosomes (Fig. 5F, G; red and blue). First, we used a dominant-negative form of

Tak1 (*Tak1^{DN}*) and *bsk* (*bsk^{DN}*) together with *PGRP-LCx^{OE}* to confirm that PGRL-LC-induced

apoptosis of TTCs is mediated by JNK. Concurrent expression of *PGRP-LCx^{OE}* with either

Tak1^{DN} or *bsk^{DN}* rescued the apoptotic phenotype (Fig. 5B, F, G). Fos and Jun proteins form

homo- or heterodimers that act as AP-1 transcription factors, also a canonical target of the

JNK pathway. To target AP-1, we focused on the *Drosophila* Fos ortholog kayak (kay). We

co-expressed a dominant-negative *kay* allele (*kay^{DN}*) together with *PGRP-LCx^{OE}* in TTCs.

Although *kay^{DN}* rescued the *PGRP-LCx^{OE}* phenotype with respect to the number and length

of branches, it was not complete (Fig. 5C, F, G; red). Co-expression of *foxo^{RNAi}* rescued the

PGRP-LCx^{OE} phenotype to the same level as *kay^{DN}* (Fig. 5D, F, G; red). RNAi of *Ets21C*

failed to rescue the *PGRP-LCx^{OE}* phenotype (Fig. 5E, F, G; blue); rather, it worsened the

phenotype with respect to the number and length of branches.

Because depletion of the TFs foxo and kayak rescued the TTC phenotype induced by *PGRP-*

LCx overexpression, we next tested whether upregulation of either induces a similar TTC

phenotype (Fig. 5H–K). Overexpression of *foxo* led to a slightly reduction in the number and

length of the branches (Fig. 5 H–J), while overexpression of a combination of *kay* and *Jra*,

which drives concurrent overexpression of both AP-1 components, led to a severe reduction

in number and length of the branches, to levels below that induced by *PGRP-LCx*

overexpression (Fig. 5 H–J, K). Therefore, we asked whether foxo and AP-1 are present and

active in TTCs. To do this, we used an AP-1 responsive TRE-RFP reporter line to detect AP-1

activity in TTCs (*28*). We observed AP-1 activity in wild-type TTCs, and even stronger

activity upon overexpression of *PGRP-LCx* (Fig. 5L, M). When we used a *Gal4* line with a

foxo promoter, we observed strong *foxo* promoter activity in all TTCs (Fig. 5N). Thus, both

TFs appear to be expressed and functional in TTCs.

Foxo controls TTC branching under normal conditions and under conditions of oxygen

deprivation

A previous study reported a role for foxo in maintaining homeostasis of tracheal epithelial

cells (*13*). One of the main features that ensures full functionality of TTCs under changing

conditions is the ability to adapt to local hypoxia to maintain the supply of oxygen to target

tissues; therefore, we subjected wild-type larvae and larvae with foxo-RNAi in TTCs to mild

hypoxia (5% O_2) and measured their branching ability (Fig. 6). As expected, wild-type TTCs

responded with increased branching (Fig. 6 A, B, E). The $foxo^{RNAi}$ TTCs already had an

increased number of branches under control conditions (21% O_2; Fig. 6C–E), and the number

of branches did not increase further after oxygen deprivation; this suggest that foxo is

required for appropriate responses to hypoxic conditions (Fig. 6D, E).

In summary, the data suggest that TTCs differ from the other parts of the tracheal system in

terms of immune pathway activation (Imd/JNK); this is a mechanism that circumvents cell

death and prevents impairment of functionality (Fig. 7A). The Imd pathway receptor *PGRP-*

LCx does not appear to be expressed in TTCs, indicating that no downstream signaling takes

place (Fig. 7B). Ectopic expression of *PGRP-LCx* exclusively in these cells leads to JNK-

mediated cell death; however, all downstream components must be present and functional.

We have shown that depletion of the JNK-associated TFs AP-1 and foxo can rescue the

PGRP-LCx-mediated phenotype. Both are present under physiological conditions, and their

overexpression can induce a severe TTC phenotype. In addition, the universal transcription

factor foxo, which is not only associated with JNK signaling, plays a role in branching of

TTCs under normal and hypoxic conditions, indicating its importance for TTC homeostasis.

DISCUSSION

Activation of the immune system is a double-edged sword in that although it fights infection,

it can also damage the organism's tissues (*29*); therefore, appropriate regulation and restriction

of the immune system is of prime importance. Tight regulation of the immune system is

essential when delicate, sensitive tissues are involved, or when immune-relevant signaling

pathways are also needed for other cellular functions. Tracheal TTCs appear to fall into both

categories; they are susceptible due to their specific structure but require foxo signaling to

maintain structural plasticity. Here, we found that TTCs, in contrast to the other epithelial

cells in the trachea, barely respond to bacterial infection. Immune-privileged status might

protect TTCs from damage caused by a strong immune response, a strategy that also protects

other organ systems (*30–32*). Here, we found that the entire tracheal epithelium expressed the

transmembrane receptor PGRP-LC, but not TTCs. We propose that the lack of *PGRP-LCx*

expression by TTCs is the reason for their lack of an immune response. This hypothesis is

supported by the observation that targeted overexpression of *PGRP-LC* in TTCs induced an

immune response, suggesting that all other pathway components are active in these cells.

Since targeted overexpression of *PGRP-LC* leads to degeneration and, ultimately, apoptosis of

these cells, this finding is particularly interesting. Targeted induction of apoptosis in TTCs by

hid and *rpr* induced a similar, but more severe, phenotype; indeed, these larvae die after

complete ablation of the cells.

Herein, we show that A) TTCs respond to a strong immune response by undergoing

apoptosis, which leads to the death of the animal; and B) that immune activation is prevented

by a lack of expression of the central receptor of the Imd pathway, PGRP-LCx. To better

understand the first finding, we needed to elucidate the mechanism of apoptosis induction on

the one hand and to identify mechanisms that still protect against infection on the other.

Activation of the Imd pathway by ectopic expression of *PGRP-LCx* throughout the trachea

leads to JNK-dependent meta- and hyperplasia of the trunk cells (*13*). The JNK pathway, as

well as activation of its canonical TFs, is associated with both proliferation and apoptosis. The

intertwining of the Imd pathway with the JNK pathway occurs at the level of Tak1 and is a

general organizational principle within these signaling pathways. This architecture means that

strong activation of the Imd pathway in these cells also triggers the multifaceted JNK

pathway. Downstream of JNK (*bsk* in *Drosophila*), we found that foxo and AP-1 are both

necessary and sufficient for the apoptotic phenotype in TTCs. AP-1 is a classical TF that is

activated by JNK signaling. The reason underlying the incomplete rescue is unknown but

might be due to a specific role for foxo in this context.

We also demonstrated that depleting *foxo* rescues the apoptotic phenotype, at least in part.

Although the effects triggered by *foxo* depletion or *foxo* overexpression were statistically

significant, they were certainly not as strong as those triggered by AP-1. This difference in

efficiency is because the tools used to manipulate foxo (RNAi and overexpression) are much

weaker than those used to manipulate AP-1 signaling. For example, in the latter case, a

dominant-negative form of *kay* and a fully active heterodimer of *Jra* and *kay* were available;

in the case of foxo, the overexpression allele does not give rise to an activated version of *foxo*,

and RNAi is generally less effective than dominant-negative alleles. In the tracheal cells of

the dorsal trunk, and the primary and secondary branches, foxo plays a role in tracheal

remodeling downstream of Imd pathway activation (*13*). It seems reasonable then that foxo

would also be activated in TTCs downstream of Imd signaling, which would in turn disrupt

branching control and thus TTC functionality, as well as the ability to respond to

environmental changes. Our central hypothesis derived from these observations is as follows:

since foxo is essential for structural plasticity, and this property is critical for the survival of

the organism, foxo should not be activated by other signals such as those from the Imd

pathway. Foxo is activated not only by JNK signaling but also is a canonical member of the

insulin signaling pathway. Linneweber and colleagues showed that insulin signaling, and

especially the insulin receptor, is necessary for TTCs to respond (i.e., with reduced branching)

to changing nutritional conditions such as low protein concentrations in food (*15*). Moreover,

different insulin receptor alleles affect the size of TTCs (*16*). Here, we showed that foxo is

also part of this signaling pathway and that it is (presumably) required to translate different

insulin signaling activities into structural changes in TTC branching. A very similar scenario

for FoxO signaling is operative in endothelial cells (ECs). Insulin and VEGF signaling in

human ECs targets FoxO to control its transcriptional activity directly via PI3K/Akt signaling

(*35, 36*).

Following our discussion of why it is sensible and necessary to omit this vital part of

epithelial immunity from TTCs, we will focus on alternative strategies that operate to ensure

that the cells are protected against infection. The strong immune response of the tracheal

epithelium may be sufficient to protect the trachea, making an immune response in distant

TTCs unnecessary. This strong and efficient immune response in the airway epithelia includes

contact structures that connect the tracheal system with the outside world: the dorsal trunks

and the primary and secondary branches (*8, 37–39*). TTCs reside at the very ends of these

systems, so potential pathogens would have to travel a long distance and escape powerful

immune responses before reaching the TTCs. In addition, the diameters of 0.1–1 μm are so

small that most bacteria will not gain access (*3*).

The mechanisms underlying immune privilege vary. The same is true for the mechanisms that

dampen the immune response. Here, we found that the dampening of the immune response

was almost complete (based on non-expression of the proximal receptor within the canonical

signaling pathway controlling epithelial immunity). A similar strategy was reported in a

subpopulation of intestinal epithelial cells, called enterocytes that do not express the Imd

receptor *PGRP-LCx* (*40*). It was hypothesized that this prevents chronic MAMP-mediated

activation of innate epithelial immune responses in these cells, which are constantly exposed

to gut bacteria. Organs such as the liver, kidney, lymphoid organs, brain, and lung are

immunotolerant (*41*). Relevant immune pathways that induce apoptosis are dampened to

different extents. In *Drosophila* epithelia, this dampening applies primarily to the Imd

pathways because Toll signaling is not functional in these structures (*8, 42*). Interestingly, the

mammalian homolog of the Imd pathway, the TNF-α pathway, also invokes these protective

strategies. This can be seen in ECs, which are the first cells to meet pathogens in the

circulation and share some characteristics with TTCs. For example, they express several

PRRs, as well as secrete pro-inflammatory cytokines to initiate immune responses (*43*). To

prevent EC death and apoptosis, protective genes and negative feedback loops become active

when immune pathways are triggered (*44*). For example, VEGF/VEGFR signaling is

immunosuppressive (*45*) because it inhibits TNF-α induced apoptosis of ECs; VEGF inhibits

secretion of TNF in a concentration-dependent manner (*46*). For example, during

angiogenesis and VEGFR activation, ECs express the anti-apoptotic gene *surviving*, which

reduces caspase-3 activity and inhibits TNF-α-mediated apoptosis (*47*). The anti-apoptotic

gene A20, when expressed in ECs, protects them from TNF-α-induced cell death, and inhibits

inflammatory responses triggered by NF-κB activation (*48*). Trabid, the equivalent of A20 in

flies, is a negative regulator of the Imd signaling pathway (*49*). TNF-α signaling, which

induces death of various cell types, is a classical apoptotic pathway. TNF-α-induced apoptosis

is highly regulated in ECs, which resist TNF-α-induced and physiological inflammatory

apoptosis via TAK1 (*50*), which also regulates necroptosis and metastasis of ECs (*51*).

The branching process in TTCs is comparable with that observed during angiogenesis, in

which the outgrowth of new capillaries is regulated by VEGF/VEGFR signaling.

Angiogenesis is influenced by events that induce survival or apoptosis in ECs; it can only be

maintained by EC survival or inhibition of apoptosis mediated; for example, by growth

factors such as VEGF/VEGFR and PI3K/Akt (*52*). Expression of the Ig-family member CD31

by ECs prevents cell death and renders them immune privileged (*53*). When the TNF-α

pathway is activated in ECs, CD31 is also activated; this in turn activates the Erk/Akt

pathway and subsequent exclusion of FoxO3 from the nucleus, leading ultimately to

inhibition of apoptosis *in vitro*. FoxO factors play a central role in controlling cell fate (i.e.,

apoptosis or proliferation). Constitutively active FOXO3a promotes EC apoptosis by

downregulating protective factors, whereas dominant-negative FoxO protects ECs from

apoptosis (*54*). In line with this observation, loss of *mFoxO1* from murine ECs leads to

uncontrolled overgrowth and hyperplasia. Moreover, FoxO controls endothelial quiescence by

reducing glycolysis and mitochondrial respiration (*55*). Active FoxO inhibits EC migration,

whereas its silencing has the opposite effect (*56*). By coincidence, we discovered a similar

role for foxo in *Drosophila* larval TTCs. We showed that foxo controls the branching of

TTCs. Overexpression of *foxo* led to reduced branching, whereas *foxo* depletion increased

TTC branching. We hypothesize that TTCs need to avoid activation of the Imd pathway

because they depend on foxo to maintain full functionality in response to changing

environmental conditions. The exact role of foxo in TTCs, and the signaling pathways

involved, remain to be elucidated. Our study highlights the importance of *Drosophila* TTCs as

a model for human ECs and thus may provide information that is useful for angiogenesis-

related research.

The data presented herein demonstrate how immune privilege is necessary to maintain the

functionality of specific cell types. In the case of TTCs, which should mount potent immune

responses, the architecture and interconnectivity of the Imd (TNF-α) and JNK pathways mean

that cell fate is inevitably linked to foxo. This is, however, incompatible with the role of foxo

in controlling the structure and functionality of these cells under changing conditions. For

these reasons, switching off the Imd pathway is the only solution to this dilemma.

MATERIAL AND METHODS

Fly lines and husbandry

Flies were raised on corn meal medium at 25°C. Tracheal humoral immune responses were

tracked using *Drs-GFP* (BDSC_55707), which allows measurement of the GFP-tagged

promotor activity of the antimicrobial peptide gene *Drosomycin*. The expression pattern of

PGRP-LCx was analyzed by crossing *PGRP-LCx-Gal4* (BDSC_77776) flies with *UAS-GFP*

(BDSC_52262) flies. Tracheal driver lines *ppk4-Gal4* (*57*) and *btl-Gal4; UAS-GFP* (Leptin

Group, EMBL Heidelberg), or TTC driver line *UAS-GFP; DSRF-Gal4* (*58*)), were crossed to

the corresponding responder lines *UAS-PGRP-LCx(III)* (Kathryn Anderson, New York),

UAS-PGRP-LC(II) (BDSC_30918), *UAS-PGRP-LE* (*Dipt.-lacZ,UAS-Flag-PGRP-LE/CyO*,

Shoichiro Kurata, Sendai), *UAS-Rel68* (BDSC_55777), *UAS-Tak1* (BDSC_58810), *UAS-*

hid;rpr (*UAS-hid; rpr;* Christian Wegener, Würzburg), *UAS-bsk^{OE}* (BDSC_9310), TRE-RFP

attP40 (Chatterjee & Bohmann 2012), *UAS-bsk^{DN}* (BDSC_44801), *UAS-kay^{DN}* (BDSC_7214),

UAS-Ets21C^{RNAi} (BDSC_39069), *UAS-foxo^{RNAi}* (BDSC_27656), *UAS-kay^{OE}* (BDSC_7213),

and *UAS-Jra^{OE}* (BDSC_7216), or *w^{1118}* (for control crossing, BDSC_5905).

Infection experiments

Natural infection of larvae was performed as described (*10*) (*9*). The gram-negative bacterium

Erwinia carotovora (Ecc-15, 2141) was cultured overnight at 30°C in LB broth. The bacteria

were pelleted by centrifugation for 20 min at $3200 \times$ g, resuspended in PBS, and absorbance

at OD_{600} measured. Next, 200 µl of the bacteria solution ($OD_{600} = 160$) was dropped into a

vial containing developing 2nd or early 3rd instar larvae (3 days after egg laying) in standard

cornmeal medium. After 24 h, the 3rd instar larvae were used for microscopy. The larvae were

heat killed in a drop of glycerol at 70°C for 20–25 s and arranged on a microscopy slide with

the dorsal side facing up. GFP expression in the tracheal DB and TTC between the dorsal

trunks was analyzed.

Branching analysis

The 3rd instar larvae were washed in PBS and deposited on a slide in a drop of glycerol. The

larvae were heat killed at 70°C for 20–25 s and arranged dorsal side up before microscopy.

Images of the TTCs were taken using the GFP channel (at 10× or 20× magnification). The

right TTC from the 3rd dorsal segment was chosen for analysis. Images were taken by an Axio

Imager.Z1 (Zeiss, Munich, Germany) with ApoTome in Z-stack mode to capture all TTC

branches. Measurement of the number and length of TTC branches was undertaken using the

ImageJ plugin NeuronJ (*59*). The branches were measured, as described previously (*60*).

Immunohistochemistry and microscopy

For microscopic and immunohistochemical analyses of intestinal TTCs, the gut of 3rd instar

larvae (along with the connected TTCs) was dissected. As an alternative, a fillet dissection for

the cuticle-attached TTCs was used for microscopy. The tissue was dissected in PBS, fixed

with 4% PFA, and blocked with 5% normal goat serum (Sigma-Aldrich, Munich, Germany)

before overnight incubation at 4°C with an anti-GFP antibody (1:200, DSHB, Iowa City,

USA). Cells were also stained with anti-Dcp-1 (1:200, Cell Signaling Technology, Danvers,

USA), anti-pJNK (Promega, V7931), and anti-Relish-C (DSHB, 21F3). Images were taken

with an Axio Imager.Z1 (Zeiss, Munich, Germany) with ApoTome in the Z-stack mode.

Hypoxia sensitivity assay

The 3rd instar larvae were washed with PBS and placed into a new food vial with a scratched

surface; 20 larvae were used per replicate. The vials were incubated for at least 10 min until

all larvae were buried in the food, and then deposited in a sealed desiccator. Nitrogen gas was

introduced until the O_2 concentration reached 2–5%. This O_2 level was maintained for 25 min.

The number of larvae outside of the food was counted every 5 min.

References

1. J. M. Whitten, The Post-embryonic Development of the Tracheal System in Drosophila melanogaster. *Journal of Cell Science*. **S3-98**, 123–150 (1957).

2. A. Uv, R. Cantera, C. Samakovlis, Drosophila tracheal morphogenesis: intricate cellular solutions to basic plumbing problems. *Trends in cell biology*. **13**, 301–309 (2003).

3. J. Jarecki, E. Johnson, M. A. Krasnow, Oxygen regulation of airway branching in Drosophila is mediated by branchless FGF. *Cell*. **99**, 211–220 (1999).

4. L. Centanin, T. A. Gorr, P. Wappner, Tracheal remodelling in response to hypoxia. *Journal of insect physiology*. **56**, 447–454 (2010).

5. L. Centanin, A. Dekanty, N. Romero, M. Irisarri, T. A. Gorr, P. Wappner, Cell autonomy of HIF effects in Drosophila: tracheal cells sense hypoxia and induce terminal branch sprouting. *Developmental cell*. **14**, 547–558 (2008).

6. A. Horowitz, M. Simons, Branching morphogenesis. *Circulation research*. **103**, 784–795 (2008).

7. M. N. Faisal, J. Hoffmann, S. El-Kholy, K. Kallsen, C. Wagner, I. Bruchhaus, C. Fink, T. Roeder, Transcriptional regionalization of the fruit fly's airway epithelium. *PloS one*. **9**, e102534 (2014).

8. C. Wagner, K. Isermann, H. Fehrenbach, T. Roeder, Molecular architecture of the fruit fly's airway epithelial immune system. *BMC genomics*. **9**, 446 (2008).

9. P. Tzou, S. Ohresser, D. Ferrandon, M. Capovilla, J. M. Reichhart, B. Lemaitre, J. A. Hoffmann, J. L. Imler, Tissue-specific inducible expression of antimicrobial peptide genes in Drosophila surface epithelia. *Immunity*. **13**, 737–748 (2000).

10. I. Akhouayri, C. Turc, J. Royet, B. Charroux, Toll-8/Tollo negatively regulates antimicrobial response in the Drosophila respiratory epithelium. *PLoS pathogens*. **7**, e1002319 (2011).

11. N. Silverman, R. Zhou, R. L. Erlich, M. Hunter, E. Bernstein, D. Schneider, T. Maniatis,

Immune activation of NF-kappaB and JNK requires Drosophila TAK1. *The Journal of*

biological chemistry. **278**, 48928–48934 (2003).

12. C. Wagner, K. Isermann, T. Roeder, Infection induces a survival program and local

remodeling in the airway epithelium of the fly. *FASEB journal : official publication of the*

Federation of American Societies for Experimental Biology. **23**, 2045–2054 (2009).

13. C. Wagner, K. Uliczka, J. Bossen, X. Niu, C. Fink, M. Thiedmann, M. Knop, C. Vock, A.

Abdelsadik, U. M. Zissler, K. Isermann, H. Garn, M. Pieper, M. Wegmann, A. R.

Koczulla, C. F. Vogelmeier, C. B. Schmidt-Weber, H. Fehrenbach, P. König, N.

Silverman, H. Renz, P. Pfefferle, H. Heine, T. Roeder, Constitutive immune activity

promotes JNK- and FoxO-dependent remodeling of Drosophila airways. *Cell reports*. **35**,

108956 (2021).

14. D. M. Wong, Z. Shen, K. E. Owyang, J. A. Martinez-Agosto, Insulin- and warts-

dependent regulation of tracheal plasticity modulates systemic larval growth during

hypoxia in Drosophila melanogaster. *PloS one*. **9**, e115297 (2014).

15. G. A. Linneweber, J. Jacobson, K. E. Busch, B. Hudry, C. P. Christov, D. Dormann, M.

Yuan, T. Otani, E. Knust, M. de Bono, I. Miguel-Aliaga, Neuronal control of metabolism

through nutrient-dependent modulation of tracheal branching. *Cell*. **156**, 69–83 (2014).

16. A. S. Burguete, D. Francis, J. Rosa, A. Ghabrial, The regulation of cell size and branch

complexity in the terminal cells of the Drosophila tracheal system. *Developmental*

biology. **451**, 79–85 (2019).

17. A. Takehana, T. Katsuyama, T. Yano, Y. Oshima, H. Takada, T. Aigaki, S. Kurata,

Overexpression of a pattern-recognition receptor, peptidoglycan-recognition protein-LE,

activates imd/relish-mediated antibacterial defense and the prophenoloxidase cascade in

Drosophila larvae. *Proceedings of the National Academy of Sciences of the United States*

of America. **99**, 13705–13710 (2002).

18. A. Takehana, T. Yano, S. Mita, A. Kotani, Y. Oshima, S. Kurata, Peptidoglycan
recognition protein (PGRP)-LE and PGRP-LC act synergistically in Drosophila immunity.
The EMBO journal. **23**, 4690–4700 (2004).

19. M. E. Grether, J. M. Abrams, J. Agapite, K. White, H. Steller, The head involution
defective gene of Drosophila melanogaster functions in programmed cell death. *Genes &*
development. **9**, 1694–1708 (1995).

20. K. White, M. E. Grether, J. M. Abrams, L. Young, K. Farrell, H. Steller, Genetic control
of programmed cell death in Drosophila. *Science (New York, N.Y.)*. **264**, 677–683 (1994).

21. T. Sarkissian, A. Timmons, R. Arya, E. Abdelwahid, K. White, Detecting apoptosis in
Drosophila tissues and cells. *Methods (San Diego, Calif.)*. **68**, 89–96 (2014).

22. T. Adachi-Yamada, K. Fujimura-Kamada, Y. Nishida, K. Matsumoto, Distortion of
proximodistal information causes JNK-dependent apoptosis in Drosophila wing. *Nature*.
400, 166–169 (1999).

23. Y. Takatsu, M. Nakamura, M. Stapleton, M. C. Danos, K. Matsumoto, M. B. O'Connor,
H. Shibuya, N. Ueno, TAK1 Participates in c-Jun N-Terminal Kinase Signaling during
Drosophila Development. *Molecular and Cellular Biology*. **20**, 3015–3026 (2000).

24. J. Mundorf, C. D. Donohoe, C. D. McClure, T. D. Southall, M. Uhlirova, Ets21c Governs
Tissue Renewal, Stress Tolerance, and Aging in the Drosophila Intestine. *Cell reports*. **27**,
3019-3033.e5 (2019).

25. F. Hafezi, J. P. Steinbach, A. Marti, K. Munz, Z. Q. Wang, E. F. Wagner, A. Aguzzi, C. E.
Remé, The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors
in retinal degeneration in vivo. *Nature medicine*. **3**, 346–349 (1997).

26. M. Lehmann, C. Jiang, Y. T. Ip, C. S. Thummel, AP-1, but not NF-kappa B, is required
for efficient steroid-triggered cell death in Drosophila. *Cell death and differentiation*. **9**,
581–590 (2002).

27. X. Luo, O. Puig, J. Hyun, D. Bohmann, H. Jasper, Foxo and Fos regulate the decision

between cell death and survival in response to UV irradiation. *The EMBO journal*. **26**,

380–390 (2006).

28. N. Chatterjee, D. Bohmann, A versatile ΦC31 based reporter system for measuring AP-1

and Nrf2 signaling in Drosophila and in tissue culture. *PloS one*. **7**, e34063 (2012).

29. W. E. Ruff, T. M. Greiling, M. A. Kriegel, Host-microbiota interactions in immune-

mediated diseases. *Nature reviews. Microbiology*. **18**, 521–538 (2020).

30. J. V. Forrester, H. Xu, T. Lambe, R. Cornall, Immune privilege or privileged immunity?

Mucosal immunology. **1**, 372–381 (2008).

31. I. Galea, I. Bechmann, V. H. Perry, What is immune privilege (not)? *Trends in*

immunology. **28**, 12–18 (2007).

32. M. A. Hill, J. H. Kwon, B. Gerry, W. A. Hardy, O. A. Walkowiak, M. N. Kavarana, S. N.

Nadig, T. K. Rajab, Immune Privilege of Heart Valves. *Frontiers in Immunology*. **12**,

731361 (2021).

33. K.-M. Choe, H. Lee, K. V. Anderson, Drosophila peptidoglycan recognition protein LC

(PGRP-LC) acts as a signal-transducing innate immune receptor. *Proceedings of the*

National Academy of Sciences of the United States of America. **102**, 1122–1126 (2005).

34. C. Neyen, M. Poidevin, A. Roussel, B. Lemaitre, Tissue- and ligand-specific sensing of

gram-negative infection in drosophila by PGRP-LC isoforms and PGRP-LE. *Journal of*

immunology (Baltimore, Md. : 1950). **189**, 1886–1897 (2012).

35. M. R. Abid, S. Guo, T. Minami, K. C. Spokes, K. Ueki, C. Skurk, K. Walsh, W. C. Aird,

Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial

cells. *Arteriosclerosis, thrombosis, and vascular biology*. **24**, 294–300 (2004).

36. M. R. Abid, S.-C. Shih, H. H. Otu, K. C. Spokes, Y. Okada, D. T. Curiel, T. Minami, W.

C. Aird, A novel class of vascular endothelial growth factor-responsive genes that require

forkhead activity for expression. *The Journal of biological chemistry*. **281**, 35544–35553 (2006).

37. M. M. Davis, Y. Engström, Immune response in the barrier epithelia: lessons from the fruit fly Drosophila melanogaster. *Journal of innate immunity*. **4**, 273–283 (2012).

38. G. P. League, J. F. Hillyer, Functional integration of the circulatory, immune, and respiratory systems in mosquito larvae: pathogen killing in the hemocyte-rich tracheal tufts. *BMC biology*. **14**, 78 (2016).

39. J. Bossen, J.-P. Kühle, T. Roeder, The tracheal immune system of insects - A blueprint for understanding epithelial immunity. *Insect biochemistry and molecular biology*. **157**, 103960 (2023).

40. C. Fink, J. Hoffmann, M. Knop, Y. Li, K. Isermann, T. Roeder, Intestinal FoxO signaling is required to survive oral infection in Drosophila. *Mucosal immunology*. **9**, 927–936 (2016).

41. J. Amersfoort, G. Eelen, P. Carmeliet, Immunomodulation by endothelial cells - partnering up with the immune system? *Nature reviews. Immunology*. **22**, 576–588 (2022).

42. D. Ferrandon, A. C. Jung, M. Criqui, B. Lemaitre, S. Uttenweiler-Joseph, L. Michaut, J. Reichhart, J. A. Hoffmann, A drosomycin-GFP reporter transgene reveals a local immune response in Drosophila that is not dependent on the Toll pathway. *The EMBO journal*. **17**, 1217–1227 (1998).

43. J. Mai, A. Virtue, J. Shen, H. Wang, X.-F. Yang, An evolving new paradigm: endothelial cells--conditional innate immune cells. *Journal of hematology & oncology*. **6**, 61 (2013).

44. F. H. Bach, W. W. Hancock, C. Ferran, Protective genes expressed in endothelial cells: a regulatory response to injury. *Immunology today*. **18**, 483–486 (1997).

45. J. Yang, J. Yan, B. Liu, Targeting VEGF/VEGFR to Modulate Antitumor Immunity. *Frontiers in Immunology*. **9** (2018).

46. I. Spyridopoulos, E. Brogi, M. Kearney, A. B. Sullivan, C. Cetrulo, J. M. Isner, D. W. Losordo, Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. *Journal of molecular and cellular cardiology*. **29**, 1321–1330 (1997).

47. D. S. O'Connor, J. S. Schechner, C. Adida, M. Mesri, A. L. Rothermel, F. Li, A. K. Nath, J. S. Pober, D. C. Altieri, Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells. *The American Journal of Pathology*. **156**, 393–398 (2000).

48. S. Daniel, M. B. Arvelo, V. I. Patel, C. R. Longo, G. Shrikhande, T. Shukri, J. Mahiou, D. W. Sun, C. Mottley, S. T. Grey, C. Ferran, A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. *Blood*. **104**, 2376–2384 (2004).

49. M. D. A. Fernando, I. Kounatidis, P. Ligoxygakis, Loss of Trabid, a New Negative Regulator of the Drosophila Immune-Deficiency Pathway at the Level of TAK1, Reduces Life Span. *PLoS Genetics*. **10** (2014).

50. H. Naito, T. Iba, T. Wakabayashi, I. Tai-Nagara, J.-I. Suehiro, W. Jia, D. Eino, S. Sakimoto, F. Muramatsu, H. Kidoya, H. Sakurai, T. Satoh, S. Akira, Y. Kubota, N. Takakura, TAK1 Prevents Endothelial Apoptosis and Maintains Vascular Integrity. *Developmental cell*. **48**, 151-166.e7 (2019).

51. L. Yang, S. Joseph, T. Sun, J. Hoffmann, S. Thevissen, S. Offermanns, B. Strilic, TAK1 regulates endothelial cell necroptosis and tumor metastasis. *Cell death and differentiation*. **26**, 1987–1997 (2019).

52. E. Chavakis, S. Dimmeler, Regulation of endothelial cell survival and apoptosis during angiogenesis. *Arteriosclerosis, thrombosis, and vascular biology*. **22**, 887–893 (2002).

53. K. Cheung, L. Ma, G. Wang, D. Coe, R. Ferro, M. Falasca, C. D. Buckley, C. Mauro, F. M. Marelli-Berg, CD31 signals confer immune privilege to the vascular endothelium.

Proceedings of the National Academy of Sciences of the United States of America. **112**,

E5815-24 (2015).

54. C. Skurk, H. Maatz, H.-S. Kim, J. Yang, M. R. Abid, W. C. Aird, K. Walsh, The Akt-

regulated forkhead transcription factor FOXO3a controls endothelial cell viability through

modulation of the caspase-8 inhibitor FLIP. *The Journal of biological chemistry*. **279**,

1513–1525 (2004).

55. K. Wilhelm, K. Happel, G. Eelen, S. Schoors, M. F. Oellerich, R. Lim, B. Zimmermann, I.

M. Aspalter, C. A. Franco, T. Boettger, T. Braun, M. Fruttiger, K. Rajewsky, C. Keller, J.

C. Brüning, H. Gerhardt, P. Carmeliet, M. Potente, FOXO1 couples metabolic activity and

growth state in the vascular endothelium. *Nature*. **529**, 216–220 (2016).

56. M. Potente, C. Urbich, K. Sasaki, W. K. Hofmann, C. Heeschen, A. Aicher, R. Kollipara,

R. A. DePinho, A. M. Zeiher, S. Dimmeler, Involvement of Foxo transcription factors in

angiogenesis and postnatal neovascularization. *Journal of Clinical Investigation*. **115**,

2382–2392 (2005).

57. L. Liu, W. A. Johnson, M. J. Welsh, Drosophila DEG/ENaC pickpocket genes are

expressed in the tracheal system, where they may be involved in liquid clearance.

Proceedings of the National Academy of Sciences of the United States of America. **100**,

2128–2133 (2003).

58. L. Gervais, J. Casanova, The Drosophila homologue of SRF acts as a boosting mechanism

to sustain FGF-induced terminal branching in the tracheal system. *Development

(Cambridge, England)*. **138**, 1269–1274 (2011).

59. E. Meijering, M. Jacob, J.-C. F. Sarria, P. Steiner, H. Hirling, M. Unser, Design and

validation of a tool for neurite tracing and analysis in fluorescence microscopy images.

Cytometry. Part A : the journal of the International Society for Analytical Cytology. **58**,

167–176 (2004).

60. T. A. Jones, M. M. Metzstein, A novel function for the PAR complex in subcellular

morphogenesis of tracheal terminal cells in Drosophila melanogaster. *Genetics*. **189**, 153–

164 (2011).

Acknowledgments

We would like to thank Britta Laubenstein and Christiane Sandberg for their excellent

technical assistance.

Funding

This work was supported by Christian-Albrechts University, Kiel, as part of the Leibniz

Campus EvoLung (TR, JB), by the International Max-Planck Research School for

Evolutionary Biology (RR), and by the Deutsche Forschungsgemeinschaft (DFG) (as part of

the CRC 1182 (project C2))(TR).

Author contributions

Conceptualization: JB, TR

Methodology: RR, JB

Investigation: JB, RR, JH

Visualization: JB, RR, JH

Funding acquisition: TR

Project administration: TR

Supervision: TR, JB

Writing – original draft: JB, TR

Writing – review & editing: TR, JB, RR

Competing interests

The authors declare no conflict of interest.

Figures and figure legends:

Fig. 1: Tracheal terminal cells (TTCs) show reduced immune response to natural infection. *Drs-GFP* larvae were infected with *Erwinia carotovora* for 24 h, and GFP fluorescence in the terminal structures of the tracheal system was monitored. Images were taken in the DIC (**A–H**) and GFP channels (A'-G', E, H). (**A, B**) Dorsal TTCs (A) and visceral TTCs (B) show no fluorescence. (**C**) Dorsal view of the tracheal system, showing the dorsal trunks branching into the dorsal branch (DB) and the dorsal TTCs.

(**D**) Percentage of larvae showing GFP fluorescence in the DB and TTCs. (**E–H**) TTCs

show expression of *Drs-GFP*. White arrows indicate shortened TTC branches (G).

The black arrows marks a melanization site and the arrowhead marks a translucent

branch without air filling (H). Dashed lines represent the proximal end of the TTCs.

Scale bar, 50 μm.

Fig. 2: TTCs do not express the Imd receptor PGRP-LCx. (A–D) The secreted Imd

pathway receptor *PGRP-LE* is expressed in the main parts of the tracheal system

(*ppk4>PGRP-LE (GFP-Drs)*). The arrows indicate TTCs not expressing GFP. The

dashed lines represent the proximal end of the TTC. **(A–C)** An activated immune

response in the larvae is visualized by expression of GFP-tagged *Drosomycin* (*Drs*).

(D, E) Detailed TTCs were observed in fillet preparations (D) and in the dissected

intestine (E) in both the DIC (D, E) and GFP channels (D', E'). **(F, G)** Expression of

GFP under the control of a *PGRP-LCx* promoter (*PGRP-LCx-Gal4 > UAS-GFP*)

revealed a lack of promoter activity, and expression of GFP, in TTCs on the cuticle

(F', F = merged image in DIC channel) and intestine (G', G = merged image in DIC

channel), which is in contrast to the rest of the tracheal system. **(H, I)** The TTCs in the

tracheal system are visualized by GFP expression in the cuticle (H) and intestine (I) of

wild-type larvae (*btl-Gal4; UAS-GFP*). Scale bar, 50 μm. dt = dorsal trunk.

Fig. 3: Expression of PGRP-LCx by TTCs leads to shrinkage and loss of functionality.

(**A, B**) Dorsal TTCs in the control (A) and *DSRF*-driven overexpression of *PGRP-LCx* in TTCs (B). (**C, D**) Measurement and quantification of the number (C) and length (D)

of branches (n=22–45). Data are presented as the mean ± SD. **(E)** The hypoxia

sensitivity assay was conducted with control and *PGRP-LCx*-expressing 3rd instar

larvae under hypoxic conditions (2–3 % O_2, n = 11–14). Data are presented as the

means ± SEM. Statistical significance was tested using Mann-Whitney-U test. *

$p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. **(F)** Culture vials containing

control, hid;rpr, and Tak1 larvae (*DSRF > hid;rpr/Tak1*) at 4 days post-oviposition.

(G, H) Transmission light microscopy of dissected intestines from 3rd instar larvae (F,

G) or 2nd instar larvae (H) with the connected TTCs of control (G) showing expression

of *hid;rpr* (H) or *PGRP-LCx* (I). **(J, K)** Dissected intestines from control larvae (J) or

larvae expressing *PGRP-LCx* in TTCs (K) were stained with an antibody specific for

cleaved *Drosophila* Dcp-1 (purple). **(I', J')** and then counterstained to detect GFP

(green). **(I'', J'')** Merged channels. Scale bars, 50 μm.

Fig. 4: JNK signaling is associated with impaired TTC branching. (A) Schematic showing how the PGRP-LC-activated Imd signaling pathway is subdivided into the NF-κB (Relish) and JNK (hep = JNKK, bsk = JNK) pathways. **(B–D)** Relish (B, *Rel68*), as well as constitutively active hep (C, *hep^CA*) and bsk (D, *bsk^OE*), were expressed in TTCs (*DSRF >*). **(E, F)** Measurement and quantification of the number (E) and length

Fig. 5: The TTC phenotype induced by PGRP-LCx is dependent on the transcription factors kay and foxo. (**A**) Schematic illustration of the JNK signaling pathway downstream of Tak1, which includes Ets21C, kay, and Jra (AP1). (**B–E**) *DSRF*-driven *PGRP-LCx^{OE}* in TTCs was combined with the dominant-negative form of *Tak1, bsk* (B), and *kay* (C), or with RNAi targeting *foxo* (D) or *Ets21C* (E). (**F**, **G**) Measurement and quantification of the number (**F**) and length (**G**) of branches (n=16–45). (**H–K**) Measurement and quantification of the number (H) and length (I) of GFP expressing branches in control (*w^{1118}*) and PGRP-LCx-expressing cells (n=7–45). TTCs overexpressing *foxo* (J, *foxo^{OE}*), and *kay* and *Jra* (K, *kay^{OE} + Jra^{OE}*). (**L**, **M**). TRE-RFP expression in control (L) and PGRP-LCx-expressing TTCs (M). (**N**) *Foxo* promoter activity in TTCs (*foxo-Gal4 > UAS-GFP*). Data are expressed as the mean ± SD. Statistical significance was evaluated using Mann-Whitney-U test, * p < 0.05, *** p < 0.001, **** p < 0.0001, ns = not significant. The color of the asterisk indicates the corresponding comparison. Dashed lines represent the mean control value. Scale bar, 50 μm.

Fig. 6: Targeted reduction of *foxo* expression in TTCs leads to hyperbranching. (A, B)
Representative tracheal branching in control (A) and *DSRF*-driven *foxo*^{RNAi} (B) cells
under normoxic conditions. **(C, D)** Representative images showing tracheal branching
in control (C) and *foxO*^{RNAi} (D) cells under hypoxic conditions. **(E)** Quantification of
branches in control and *DSRF > foxO*^{RNAi} TTCs under normoxic (21%) and hypoxic
(5%) conditions. Scale bar, 50 μm. n=21, Data are presented as the mean ± SD.
Statistical significance was evaluated using Mann-Whitney-U t-test, * $p < 0.05$, **** p
< 0.0001, ns = not significant.

Fig. 7: Schematic summarizing the JNK-mediated immune/stress response in the
trachea and TTCs. (A) Tracheal infection leads to an immune response involving
expression of antimicrobial peptides such as *Drosomycin* (*Drs*, green). In most cases,

the immune response is restricted to the tracheal trunks and the TTCs are unaffected

(bold arrow). In rare cases, TTCs express *Drs*, resulting in an impaired phenotype

(dashed arrow). (**B**) Imd signaling in the main tracheal trunks is induced by

peptidoglycan recognition receptors (PGRP)-LC and -LE. Downstream, the signaling

branches into a Relish (Rel) and a JNK signaling pathway. Activation of the pathways

mediates airway remodeling (*13*). However, activation in TTCs is avoided by the

absence of PGRP-LC, even though all other JNK signaling pathway components are

present. The pathway can be activated by external stressors, resulting in AP-1-

mediated cell death. The transcription factor foxo, which is component not only of the

JNK signaling pathway but also of the insulin signaling pathway, plays a role in TTC

homeostasis and their ability to branch.